Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in hepatocellular carcinoma

肝细胞癌中的基质金属蛋白酶和基质金属蛋白酶的组织抑制剂

• 批准号: 12670485
• 负责人: MURAWAKI Yoshikazu
• 金额: $ 2.05万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670485/
• 关键词: hepatocellular carcinoma; matrix metalloproteinase; TIMP; MMP-7; MMP-1; MMP-2; MMP-3; TIMP-1; TIMP-2; MMP-9; 細胞外マトリックス分解酵素

In general, matrix metalloproteinases (MMPs) are involved in growth and invasion of cancer. In this study, we examined the clinical significance of serum levels of MMP-1, proMMP-1, active MMP-2, proMMP-2, MMP-3, MMP-7, TIMP-1 and TIMP-2 in patients with hepatocellular carcinoma (HCC), and found that these serum levels in HCC patients were somewhat higher than in cirrhotic patients, and were slightly related with clinical findings such as tumor size, tumor morphology, histological differentiation, and portal thrombosis. Among these tests, TIMP-1 was the most closely related marker with the clinical findings of HCC. In addition, we compared the expression of MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, TIMP-1 and TIMP-2 between HCC tissues and non-tumor tissues, and found that the immunohistochemical stain intensity in HCC tissues were similar to that in non-tumor tissues, suggesting that HCC cells are not the major producing cells of MMPs and TIMPs.

一般来说，基质金属蛋白酶（MMP）参与癌症的生长和侵袭。在本研究中，我们检测了肝细胞癌患者血清中 MMP-1、proMMP-1、活性 MMP-2、proMMP-2、MMP-3、MMP-7、TIMP-1 和 TIMP-2 水平的临床意义。 (HCC)，发现HCC患者的这些血清水平略高于肝硬化患者，并且与肿瘤大小、肿瘤形态、组织学分化和门静脉血栓形成等临床表现略有相关。其中，TIMP-1是与HCC临床表现最密切相关的标志物。此外,我们比较了HCC组织与非肿瘤组织中MMP-1、MMP-2、MMP-3、MMP-7、MMP-9、TIMP-1、TIMP-2的表达量,发现免疫组化染色HCC组织中的强度与非肿瘤组织相似，表明HCC细胞不是MMPs和TIMPs的主要产生细胞。

项目成果

Murawaki Y., Ikuta Y., Koda M., Okamoto K., Mimura K.: "The proMMP-2 activation rate in patients with chronic viral liver disease"Clin Chim Acta. 324. 99-103 (2002)

Murawaki Y.、Ikuta Y.、Koda M.、Okamoto K.、Mimura K.：“慢性病毒性肝病患者的 proMMP-2 激活率”Clin Chim Acta。

Murawaki Yoshikazu: "Plasma matrix metalls proteinase-9(gelatinase B) in patients with hepatocellular carcinoma"Res Commun Mol Pathol Pharmacol. 108. 351-357 (2000)

Murawaki Yoshikazu：“肝细胞癌患者的血浆基质金属蛋白酶 9（明胶酶 B）”Res Commun Mol Pathol Pharmacol。

Mimura K., Murawaki Y., Okamoto K., Matsunaga Y., Ueki M., Yamamoto R., Koda M.: "Clinical usefulness of matrix metalloproteinase-9 in chronic liver disease and hepatocellular carcinoma : Comparison with MMP-2"Jpn Pharmacol Ther. 30. s323-s330 (2002)

Mimura K.、Murawaki Y.、Okamoto K.、Matsunaga Y.、Ueki M.、Yamamoto R.、Koda M.：“基质金属蛋白酶 9 在慢性肝病和肝细胞癌中的临床用途：与 MMP-2 的比较”

Murawaki Yoshikazu: "The pro MMP-2 activation rate in patients with chronic viral liver disease"Clin Chim Acta. 324. 99-103 (2002)

Murawaki Yoshikazu：“慢性病毒性肝病患者的 MMP-2 前体激活率”Clin Chim Acta。

三村憲一: "慢性肝疾患および肝細胞癌での matrix metalloproteinase-9(gelatinase B)の臨床的意義"薬理と治療. 30. S323-S330 (2002)

Kenichi Mimura：“基质金属蛋白酶 9（明胶酶 B）在慢性肝病和肝细胞癌中的临床意义”30. S323-S330 (2002)。